# Cleara Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cleara-biotech-b-v

- Industry: Biotechnology
- Headquarters: Utrecht, Netherlands
- Website: www.clearabiotech.com
- Total disclosed funding: $2.5M
- Latest round: Seed (Feb 1, 2022)
- Investors on record: 4

## About

Based in the Netherlands, and founded in 2018, Cleara Biotech B.V. provides therapies for the treatment of different types of “senescent” cells. The company was spun out from the Medical Center Utrecht (UMCU). In September 2022, the firm raised USD 2.5 million in Seed funding led by investor Apollo Health Ventures with participation from other investors Curie Capital, Longevity Tech Fund, and ROM Utrecht Region.

The company develops the next generation of subtype-specific anti-senescence compounds which helps in restoring tissue homeostasis. Additionally, the firm offers a FOXO4-based treatment approach that uses the biomarker and eliminates the biomarker-positive scarred cells. It develops the technology against scarred cellular senescence which helps in the treatment of metastatic, mutant-p53 cancer.

The company plans to use the September 2022 funding to progress the company compounds toward clinical development and further build its developmental pipeline and management team.

## Funding rounds

- Seed, Feb 1, 2022, $2.5M — Apollo Health Ventures, Curie Capital, Longevity Tech Fund, ROM Utrecht Region

## Investors

- Apollo Health Ventures (https://capitalatlas.ai/funds/apollo-health-ventures) — Seed
- Curie Capital (https://capitalatlas.ai/funds/curie-capital) — Seed
- Longevity Tech Fund (https://capitalatlas.ai/funds/longevity-tech-fund) — Seed
- ROM Utrecht Region (https://capitalatlas.ai/funds/rom-utrecht-region) — Seed